CDC considers 'morning after' therapy for sexual exposure. Centers for Disease Control and Prevention.
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002487:Centers for Disease Control and Prevention, U.S.; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use; D008297:Male; D012309:Risk-Taking; D012725:Sexual Behavior; D014481:United States; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D015215:Zidovudine; D019469:Indinavir